Literature summary for 3.4.14.5 extracted from

Brazg, R.; Xu, L.; Dalla Man, C.; Cobelli, C.; Thomas, K.; Stein, P.P.
Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes (2007), Diabetes Obes. Metab., 9, 186-193.

Search for more literature for 3.4.14.5

Application

Application	Comment	Organism
medicine	addition of sitagliptin 50 mg b.i.d. to ongoing metformin therapy improves 24-h glycaemic control and beta-cell function, and is generally well tolerated in patients with type 2 diabetes	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
sitagliptin	addition of sitagliptin 50 mg b.i.d. to ongoing metformin therapy improves 24-h glycaemic control and beta-cell function, and is generally well tolerated in patients with type 2 diabetes	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	patients with type 2 diabetes	-

Synonyms

Synonyms	Comment	Organism
dipeptidyl peptidase-4	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)